WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Resources > Whitepapers > The public debate on agro biotechnology : a biotech company ís perspective
I'm For Real
Enter your details once to access all our information and resources
Our mission is to elevate the cannabis industry to higher medical standards by streamlining the prescription, cultivation and consumer cannabis selection process.
whitePaper | July 25, 2022
The goal of each process step is to facilitate the production of a consistent product with high yield, quality, purity, and functionality. Throughout each step various Process Analytical Tools (PAT) are used to ensure quality and production metrics are maintained.
whitePaper | April 8, 2020
The rapid spread of the novel coronavirus across the globe is a major public health threat for all, with profound health, social and economic impacts around the world. As a science-driven industry that aims to address some of the world’s biggest healthcare challenges, the research-based biopharmaceutical industry is uniquely positioned to respond rapidly to COVID-19. It has deep scientific knowledge gained from decades of experience working on developing solutions for combatting a range of infectious diseases such as MERS, SARS, Ebola and influenza.
whitePaper | June 23, 2022
Cell and gene therapies require both efficient and reliable freeze-thaw systems. Building the most effective system depends on selecting the right materials and instruments.
whitePaper | August 19, 2021
DNA storage technology is advancing rapidly. Atos is closely monitoring the development of this technology in the hope that future developments will make it a scalable, cost effective and crucially a decarbonized alternative to today’s carbon intensive technologies.
whitePaper | March 12, 2022
CRISPR, gene editing, biotech, precision agriculture and automation influencing the future of business, government, food, medicine, geopolitics and society
whitePaper | April 24, 2023
Despite challenging global conditions, the Swiss biotech industry was able to raise more than CHF 1.33 billion in 2022, with roughly CHF 0.78 billion collected by public companies and the remaining CHF 0.55 billion collected by private companies.
Conference
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE